Literature DB >> 475429

Carbamazepine dose-frequency requirement in children.

G W Rylance, T A Moreland, G M Butcher.   

Abstract

The dose-frequency requirement for carbamazepine (CBZ) in children was investigated using serial saliva samples to determine the daily fluctuation in drug levels. Mixed saliva was collected from 6 children (aged between 6 and 13 years) in a steady state, on each of two different dose-frequency resulted in smaller fluctuations in saliva concentration and a shorter time with levels outside the therapeutic range. Toxic features and convulsions appeared to be related to peak and trough concentrations. There was no apparent relationship between the total dose and the mean saliva concentration. The saliva CBZ half-lives in 2 children were 7.3 and 12.7 hours, and the apparent volumes of distribution (saliva) were 1.6 and 1.5 l/kg respectively. Saliva CBZ concentrations are an efficient and convenient means of tailoring individual dosage, and can be used to provide the pharmacokinetic data that rational prescribing demands.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 475429      PMCID: PMC1545436          DOI: 10.1136/adc.54.6.454

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  20 in total

1.  DIPHENYLHYDANTOIN AND PHENOBARBITAL. SERUM LEVELS IN CHILDREN.

Authors:  O SVENSMARK; F BUCHTHAL
Journal:  Am J Dis Child       Date:  1964-07

2.  Use of saliva in monitoring carbamazepine medication in epileptic children.

Authors:  H Bartels; H D Oldigs; E Günther
Journal:  Eur J Pediatr       Date:  1977-08-23       Impact factor: 3.183

Review 3.  Usefulness of blood levels of antiepileptic drugs.

Authors:  H Kutt; J K Penry
Journal:  Arch Neurol       Date:  1974-11

4.  Management of epilepsy with diphenylhydantoin sodium. Dosage regulation for problem patients.

Authors:  H Kutt; F McDowell
Journal:  JAMA       Date:  1968-03-11       Impact factor: 56.272

5.  Saliva carbamazepine levels in children.

Authors:  G W Rylance; G M Butcher; T Moreland
Journal:  Br Med J       Date:  1977-12-03

6.  Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses.

Authors:  M Eichelbaum; K Ekbom; L Bertilsson; V A Ringberger; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1975-06-13       Impact factor: 2.953

7.  Salivary levels of anticonvulsants: a practical approach to drug monitoring.

Authors:  J J McAuliffe; A L Sherwin; I E Leppik; S A Fayle; C E Pippenger
Journal:  Neurology       Date:  1977-05       Impact factor: 9.910

8.  Kinetics of carbamazepine and carbamazepine-epoxide, determined by use of plasma and saliva.

Authors:  H G Westenberg; E van der Kleijn; T T Oei; R A de Zeeuw
Journal:  Clin Pharmacol Ther       Date:  1978-03       Impact factor: 6.875

9.  A method for obtaining saliva samples from infants and young children.

Authors:  C J Bacon; J C Mucklow; A Saunders; M D Rawlins; J K Webb
Journal:  Br J Clin Pharmacol       Date:  1978-01       Impact factor: 4.335

10.  Salivary phenytoin concentrations in epilepsy and in chronic renal failure.

Authors:  F Reynolds; P N Ziroyanis; N F Jones; S E Smith
Journal:  Lancet       Date:  1976-08-21       Impact factor: 79.321

View more
  12 in total

1.  A descriptive systematic review of salivary therapeutic drug monitoring in neonates and infants.

Authors:  Laura Hutchinson; Marlene Sinclair; Bernadette Reid; Kathryn Burnett; Bridgeen Callan
Journal:  Br J Clin Pharmacol       Date:  2018-03-25       Impact factor: 4.335

Review 2.  Drug level monitoring in paediatric practice.

Authors:  G W Rylance; T A Moreland
Journal:  Arch Dis Child       Date:  1980-02       Impact factor: 3.791

3.  Saliva carbamazepine and phenytoin level monitoring.

Authors:  G W Rylance; T A Moreland
Journal:  Arch Dis Child       Date:  1981-08       Impact factor: 3.791

4.  Rapid and sensitive high-pressure liquid chromatographic method for monitoring carbamazepine levels in serum.

Authors:  M Furlanut; M G Delucca; G Dilberis; A Barnaba
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

5.  Daily variations in steady-state plasma concentrations of carbamazepine and its metabolites in epileptic children.

Authors:  R Hartley; W I Forsythe; B McLain; P C Ng; M D Lucock
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

Review 6.  Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.

Authors:  E Yukawa
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

7.  Saliva carbamazepine levels in children before and during multiple dosing.

Authors:  T A Moreland; D A Priestman; G W Rylance
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

Review 8.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

9.  Carbamazepine 10,11-epoxide in children.

Authors:  G W Rylance; C Edwards; P R Gard
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

Review 10.  Pharmacokinetic optimisation of anticonvulsant therapy.

Authors:  A H Thomson; M J Brodie
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.